Chaga mushroom: the oxalate kidney risk the wellness market ignores

Chaga (Inonotus obliquus) has become a fixture of immune and anti-aging supplement lines, but published case reports of acute oxalate nephropathy with permanent kidney injury — including patients requiring dialysis — exist. The risk is dose-dependent, predictable from the basic chemistry of the mushroom, and almost entirely absent from product marketing.

What chaga actually contains

Chaga is a parasitic polypore that grows on birch trees in northern climates. The sclerotium (the woody black mass harvested for supplements) contains beta-glucans, polyphenolics, melanin pigments, betulinic acid derivatives, and a notably high concentration of oxalate. Oxalate content varies by source but reported figures range from 11,000 to 21,000 mg per 100 g of dried material — among the highest of any commonly consumed botanical.

Oxalate nephropathy: the documented harms

A 2014 Japanese case report described a 72-year-old woman with hepatocellular carcinoma who developed end-stage renal disease after consuming approximately 4–5 g of chaga powder daily for 6 months [1]. Renal biopsy showed extensive calcium oxalate crystal deposition. A 2020 case from China described acute renal failure with biopsy-confirmed oxalate crystals in a patient consuming a chaga decoction [2]. Smaller reports have continued to appear in nephrology literature.

Who is at elevated risk

Anyone with prior kidney disease, diabetes, hypertension, dehydration, or a history of calcium oxalate kidney stones is at significantly elevated risk. Concurrent vitamin C megadosing (which generates endogenous oxalate) compounds the issue. Liver disease may also increase risk by reducing endogenous oxalate clearance routes. Pregnancy is a relative contraindication because of glomerular hyperfiltration.

Drug interactions

Chaga has mild anticoagulant activity and case reports describe bleeding-risk interactions with warfarin. Theoretical interactions with antidiabetic agents (hypoglycemic effect in some animal models) and with hepatically cleared drugs have been described but lack robust human data. The kidney risk dwarfs these in clinical importance.

What the efficacy data actually show

Despite extensive marketing claims for immune support, anti-cancer activity, and anti-aging, human trials of chaga are nearly absent. Polysaccharide fractions show immunomodulatory activity in cell and rodent work, but the leap to human clinical benefit is unsupported. The risk-benefit calculation therefore tilts heavily toward the documented harm side.

Safer dosing patterns if used at all

If chaga is to be used, the published case reports suggest that exposures below approximately 1 g of dried equivalent per day, taken with adequate fluids, with no underlying renal risk factors, and for limited courses (under one month at a time) are the floor of caution rather than a guarantee of safety. There is no well-defined safe dose because dose-response data in humans do not exist.

The bottom line

Chaga has documented case-report-level potential for severe, irreversible kidney injury through oxalate nephropathy. The efficacy evidence in humans is essentially absent. Patients with any kidney risk factor — diabetes, hypertension, prior stones, advanced age, dehydration risk — should not use it. Healthy adults using it briefly with attention to hydration are at low but non-zero risk. The wellness category's enthusiasm for chaga is not in proportion to the published harm-to-benefit ratio.